| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/21/2004 | US6794359 Vertebrate intestinal protein which absorbs cholesterol, its inhibitors and mehtod of identifying the same |
| 09/21/2004 | US6794178 Nucleotide sequences coding transport protein for us in the treatment and diagnosis of cancer, arthritis, vision defects and skin dsorders |
| 09/21/2004 | US6793946 Tea comprsing persea americana var. drymifolia leaves |
| 09/21/2004 | CA2189297C Process for preparing 1-substituted pyrrole-3-carboxylic acid derivatives |
| 09/21/2004 | CA2167673C Condensed benzazepine derivative and pharmaceutical composition thereof |
| 09/21/2004 | CA2114017C Amide tetrazole acat inhibitors |
| 09/21/2004 | CA2100381C N-derivatives of (phenylethyl-.beta.-ol) amine, a process for their preparation and pharmaceutical compositions containing the same |
| 09/21/2004 | CA2076226C Substituted 1-pyrimidinylacetamide compounds |
| 09/16/2004 | WO2004078942A2 Endothelial cell specific antibodies and uses thereof |
| 09/16/2004 | WO2004078741A1 Adiponectin expression promoter |
| 09/16/2004 | WO2004078723A1 Novel compound having 4-pyridylalkylthio group as substituent |
| 09/16/2004 | WO2004078719A1 Indole derivative compounds and drugs containing the compounds as the active ingredient |
| 09/16/2004 | WO2004078208A1 MEDICINAL USE OF MIP-3α INHIBITOR AND METHOD OF SCREENING BRAIN/NERVE CELL PROTECTIVE AGENT |
| 09/16/2004 | WO2004078192A1 Use of tumor endothelial markers 1, 9 and 17 to promote angiogenesis |
| 09/16/2004 | WO2004078169A1 Use of ep2 selective receptor agonists in medical treatment |
| 09/16/2004 | WO2004078166A2 Use of omega-3-fatty acids in the treatment of diabetic patients |
| 09/16/2004 | WO2004078140A2 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF |
| 09/16/2004 | WO2004077963A1 Processed plant product and method of producing the same |
| 09/16/2004 | WO2004062592A3 2-o sulfatase compositions and related methods |
| 09/16/2004 | WO2004062557A3 Pharmaceutical combination of telmisartan and atorvastatin for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
| 09/16/2004 | WO2004047837A3 Beta-blockers having antioxidant and nitric oxide-donor activity |
| 09/16/2004 | WO2003105666A3 Method of treating ischemia reperfusion injury using adenosine receptor antagonists |
| 09/16/2004 | WO2003095398A3 Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same |
| 09/16/2004 | WO2003052048A3 Nucleic acid-associated proteins |
| 09/16/2004 | WO2003028729A3 Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 09/16/2004 | US20040181125 Cardiac disease treatment and device |
| 09/16/2004 | US20040181123 Cardiac disease treatment and device |
| 09/16/2004 | US20040181122 Cardiac disease treatment and device |
| 09/16/2004 | US20040181121 Cardiac disease treatment and device |
| 09/16/2004 | US20040181073 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils |
| 09/16/2004 | US20040181062 Benzimidazole cyclooxygenase-2 inhibitor |
| 09/16/2004 | US20040181060 that bear a N-2-(alkoxycarbonylamino)ethyl substituent; intermediates in the synthesis of 1,3-diaza-6-oxa-adamantanes |
| 09/16/2004 | US20040181059 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 09/16/2004 | US20040181047 33 human secreted proteins |
| 09/16/2004 | US20040181035 Modified colony stimulating factor for treatment of hematopoietic disorder |
| 09/16/2004 | US20040181034 Multimeric Apo A-I agonist compounds |
| 09/16/2004 | US20040181032 for promoting the release of growth hormone and of enhancing wound healing in a human or animal subject; for treating short stature, cachexia, wasting, type 2 diabetes, and poor circulation |
| 09/16/2004 | US20040180963 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
| 09/16/2004 | US20040180952 Derivatives of (-)- and (+)-venlafaxine and methods of preparing and using the same |
| 09/16/2004 | US20040180944 Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction |
| 09/16/2004 | US20040180938 More preferred compound is (1Z,3E)-1-methyl-1-(4-carboxyphenyl)-2-methoxycarbonyl-3-(2-methylpyridin-4-yl)aminocarbonyl-4-(3-methoxyphenyl)butadiene; for the treatment of acute coronary symptoms |
| 09/16/2004 | US20040180936 having an inhibitory activity on calpains and/or a trapping activity on reactive oxygen species; inflammatory and immunological diseases; disorders of the central or peripheral nervous system |
| 09/16/2004 | US20040180925 such as (S)-1-[2-(2-Pyrazinylamino)ethylamino]acetyl-2-pyrrolidinecarbonitrile dimethanesulfonate |
| 09/16/2004 | US20040180924 Novel heterocyclic derivatives and medicinal use thereof |
| 09/16/2004 | US20040180921 Nitrogen compounds such as 2-benzofuran-2-yl-imidazo(1,2-a) pyridine administered as g protein coupled receptor antagonists for prophylaxis of psychological and neurodegenerative disorders, and as analgesics |
| 09/16/2004 | US20040180914 5-Cyano-2-aminopyrimidine derivatives |
| 09/16/2004 | US20040180912 for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable |
| 09/16/2004 | US20040180908 (2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol |
| 09/16/2004 | US20040180901 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
| 09/16/2004 | US20040180895 Use of a pyridazinone derivative |
| 09/16/2004 | US20040180890 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same |
| 09/16/2004 | US20040180887 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 09/16/2004 | US20040180881 Oxazolyl-pyrazole derivatives as kinase inhibitors |
| 09/16/2004 | US20040180878 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 09/16/2004 | US20040180877 Nicotinic acetylcholine receptor cholinergic ligands, monoamine receptor and transporter modulators; such as 1-(2-Benzo[b]thiophenyl-1,1-dioxide)-imidazolidine |
| 09/16/2004 | US20040180876 Selective beta 2-adrenoreceptor agonists; rapid onset of action, long duration; such as 3-(4-{[6-{(-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)benzenesulfonamide; synthesis |
| 09/16/2004 | US20040180835 Use of the protein uk114 or of fragments thereof for the treatment and prevention of the endotoxic shock |
| 09/16/2004 | US20040180821 Treatment of congestive heart failure |
| 09/16/2004 | US20040180088 Controlled release core is capable of swelling rapidly to at least about two times its original volume, and maintaining its physical integrity in gastrointestinal fluids for prolonged periods |
| 09/16/2004 | US20040180051 Comprising an antibody against human tissue factor (human TF), for therapy of pulmonary thrombosis or deep venous thrombosis |
| 09/16/2004 | US20040180040 Methods and compositions for directing cells to target organs |
| 09/16/2004 | US20040180007 Pharmaceutical chewing gum formulations |
| 09/16/2004 | DE19806354B4 Verwendung von α-Liponsäure oder deren physiologisch verträgliche Salze zur Behandlung von LDL-Hypercholesterinämie Use of α-lipoic acid or its physiologically acceptable salts for the treatment of hypercholesterolemia LDL |
| 09/16/2004 | CA2518490A1 Endothelial cell specific antibodies and uses thereof |
| 09/16/2004 | CA2518193A1 Use of ep2 selective receptor agonists in medical treatment |
| 09/16/2004 | CA2517145A1 Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 09/16/2004 | CA2517085A1 Adiponectin expression promoter |
| 09/16/2004 | CA2515328A1 Use of omega-3-fatty acids in the treatment of diabetic patients |
| 09/15/2004 | EP1457557A1 Novel proteins and dnas thereof |
| 09/15/2004 | EP1457498A1 Novel peptide having angiotensin convertase inhibitory effect |
| 09/15/2004 | EP1457495A1 Adenosine A1 receptor agonists |
| 09/15/2004 | EP1457490A1 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 09/15/2004 | EP1457205A1 Angiogenesis inhibitor |
| 09/15/2004 | EP1456670A2 Methods relating to treatment of atherosclerosis |
| 09/15/2004 | EP1456653A2 Genes encoding g-protein coupled receptors and methods of use therefor |
| 09/15/2004 | EP1456419A2 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| 09/15/2004 | EP1456403A2 Methods of using 48149, a human aminopeptidase family member |
| 09/15/2004 | EP1456402A2 Means for treatment of atherosclerosis |
| 09/15/2004 | EP1456385A2 Growth hormone fusion protein |
| 09/15/2004 | EP1456374A2 Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| 09/15/2004 | EP1456365A2 Protein modification and maintenance molecules |
| 09/15/2004 | EP1456357A2 Pluripotent embryonic-like stem cells derived from teeth and uses thereof |
| 09/15/2004 | EP1456355A2 Process for the manufacture of human mononuclear phagocytic leukocytes |
| 09/15/2004 | EP1456353A2 The use of acyl salicylates as heat shock inducers |
| 09/15/2004 | EP1456219A1 Crystalline form of a ribofuranosyluronamide derivative; a human adenosine A2a receptor agonist |
| 09/15/2004 | EP1456214A2 Improvements in pharmaceutical compositions |
| 09/15/2004 | EP1456212A1 6-aminomorphinane derivatives, method for the production and use thereof |
| 09/15/2004 | EP1456210A1 Pyrazolyl-substituted triazoloquinoxalines |
| 09/15/2004 | EP1456208A1 Pyridoquinoxaline antivirals |
| 09/15/2004 | EP1456207A2 Heterocyclic acridone inhibitors of impdh enzyme |
| 09/15/2004 | EP1456205A1 Imidazoquinoline derivatives |
| 09/15/2004 | EP1456204A1 Triazolo-quinolin derivatives useful as adenosine receptor ligands |
| 09/15/2004 | EP1456203A1 Ethylene diamine derivatives and their use as orexin-receptor antagonists |
| 09/15/2004 | EP1456202A1 Benzothiazoles |
| 09/15/2004 | EP1456200A1 Lactams as tachykinin antagonists |
| 09/15/2004 | EP1456189A1 Benzothia(dia)zine derivatives and their use as ampa modulators |
| 09/15/2004 | EP1456188A1 7-amino-benzothiazole derivatives as adenosine receptor ligands |
| 09/15/2004 | EP1456181A1 Methods for preparing sodium-hydrogen exchanger type-1 inhibitors |
| 09/15/2004 | EP1456172A1 Pyrrolidine-2-ones as factor xa inhibitors |
| 09/15/2004 | EP1456171A1 Substituted cyclohexane derivatives |